ENG and heart failure: Therefore, targeting endoglin to prevent fibrosis and heart failure may improve clinical outcome in patients with heart failure in addition to the current clinical benefits of β-adrenergic receptor antagonists, angiotensin-converting enzyme or receptor blockers and aldosterone antagonists [19].